Get started
Author

Nicola Jane Main

Observed names: N.J. Main, Nicola J Main, Nicola J. Main
Observed institution: Starpharma (Australia)
ORCID: 0009-0009-3756-4495
Observed ORCID: 0009-0009-3756-4495
OpenAlex ID: A5048642677
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).
2024 · James F. Spicer, David James Pinato, et al. · Journal of Clinical Oncology · 5
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors
2025 · Jia Liu, Anna R. Minchom, et al. · Journal of Clinical Oncology · 3
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.
2024 · Jia (Jenny) Liu, Anna Rachel Minchom, et al. · Journal of Clinical Oncology · 2
Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours
2023 · Jia Liu, Anna R Minchom, et al. · Molecular Cancer Therapeutics · 2
1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial
2022 · R.H. Jones, D.J. Pinato, et al. · Annals of Oncology · 2
PDF
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours
2026 · Robert H. Jones, David J. Pinato, et al. · European Journal of Cancer · 1
Works count: 6
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type